Clinical Trials Logo

Filter by:
NCT ID: NCT00913120 Completed - Clinical trials for Venous Thromboembolism

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery

Start date: May 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.

NCT ID: NCT00911196 Completed - Clinical trials for Hepatocellular Carcinoma

Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma

Start date: November 2008
Phase: N/A
Study type: Observational

Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these. As a first step in the development of novel therapies, expression analysis of specific markers, including tumor antigens will be carried out, and the correlation of expression with disease variables and clinical outcome will be assessed. This will be done retrospectively using archived hepatocellular carcinoma tissue samples.

NCT ID: NCT00910871 Completed - Tuberculosis Clinical Trials

To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.

Start date: September 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen (BR) of antibacterial drugs as treatment for MDR-TB

NCT ID: NCT00909597 Completed - Clinical trials for Diabetes Mellitus Type 2

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Start date: May 2009
Phase: Phase 3
Study type: Interventional

This double-blind, double-dummy 3 arm study will evaluate the efficacy, safety and tolerability of taspoglutide versus pioglitazone in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy. After an initial screening period, patients will be randomized to one of 3 groups, to receive a)taspoglutide 10mg sc weekly, b)taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly or c)pioglitazone 45mg/day po after 4 weeks of pioglitazone 30mg/day po.The anticipated time on study treatment is 24 months, and the target sample size is 500+ individuals.

NCT ID: NCT00909480 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes

EFFICACY
Start date: May 2009
Phase: Phase 4
Study type: Interventional

This trial is conducted in Asia, South America and the United States of America (USA). The aim of this clinical trial is to determine whether two insulin treatments given once daily are equally effective with respect to the blood glucose lowering effect in subjects with type 2 diabetes inadequately controlled on metformin treatment with or without an additional anti-diabetic drug (OAD).

NCT ID: NCT00909051 Completed - Diabetes Mellitus Clinical Trials

GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

Start date: March 24, 2009
Phase:
Study type: Observational

Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.

NCT ID: NCT00908752 Completed - Clinical trials for Hepatocellular Carcinoma

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

BRISK TA
Start date: July 20, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.

NCT ID: NCT00908596 Completed - Contrast Media Clinical Trials

Primovist / Eovist in Renally Impaired Patients

PERI
Start date: May 2009
Phase: Phase 4
Study type: Interventional

Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Primovist/Eovist, will be asked to participate. The administration of contrast agents that contain gadolinium such as Primovist/Eovist might increase a potential risk to develop a rare condition called nephrogenic systemic fibrosis (NSF) in patients with renal impairment. This study is to assess the potential risk to develop NSF in patients with renal impairment after the administration of Primovist/Eovist. Patients who are enrolled in this study will receive a Primovist/Eovist enhanced MRI scan which was prescribed by the referring doctor. After the MRI scan the patient will be included in a two year follow-up period to assess if signs or symptoms suggestive of NSF have appeared.

NCT ID: NCT00904358 Completed - Clinical trials for Central Venous Pressure

Estimation of Internal Jugular Vein Central Venous Pressure (CVP) by Ultrasound

Start date: May 2009
Phase: N/A
Study type: Observational

To study the validity and reliability of estimation of the central venous pressure by measurement of internal jugular vein size using 2-dimensional ultrasound.

NCT ID: NCT00903578 Active, not recruiting - Clinical trials for Kidney Transplantation

Impact of Fibroblast Growth Factor 23 (FGF-23) and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients

Start date: May 2009
Phase: N/A
Study type: Observational

The present study will examine whether serum FGF-23 and serum phosphate at baseline of kidney transplant recipients can predict progression of allograft dysfunction at 3 years and all-cause mortality at 5 years.